| 翻訳と辞書 |
| Tarenflurbil ： ウィキペディア英語版 |
Tarenflurbil
Tarenflurbil,〔(www.myriad.com ) Update on Flurizan.〕 Flurizan or ''R''-flurbiprofen, is the single enantiomer of the racemate NSAID flurbiprofen. For several years, research and trials for the drug were conducted by Myriad Genetics, to investigate its potential as a treatment for Alzheimer's disease; that investigation concluded in June 2008 when the company announced it would discontinue development of the compound.〔(Myriad Genetics Reports Results of U.S. Phase 3 Trial of Flurizan in Alzheimer's Disease ) from the Myriad Genetics website.〕
==Mechanism of action==
At proposed therapeutic concentrations, this molecule lacks anti-inflammatory activity, and does not inhibit either cyclooxygenase 1 (COX-1) or cyclooxygenase 2 (COX-2) enzymes. Only the ''S''-enantiomers of arylpropionic acid NSAID can potently inhibit COX, whereas the ''R''-enantiomers exert almost no COX activity. ''R''-Flurbiprofen is inefficiently converted into ''S''-flurbiprofen, with 1.5% of the ''R''-enantiomer undergoing bioinversion to the ''S''-form. Although this compound lacks activity against COX, studies have shown that this drug is a potent reducer of levels of beta amyloid,〔
〕 the main constituent of amyloid plaques in Alzheimer's disease, and therefore there was interest in this drug as a therapeutic agent.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Tarenflurbil」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|